Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

FORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq:STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. (“Lay Sciences”), a development and commercialization company of innovative solutions, to license worldwide manufacturing rights to certain Lay Sciences’ IgY products containing avian antibodies as an active ingredient.